|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues: | |||||
| Premiums | |||||
| Investment and other income | |||||
| Total revenues | |||||
| Revenue from Products and Services | |||||
| Products | |||||
| Services | |||||
| Operating costs: | |||||
| Medical costs | |||||
| Operating costs | |||||
| Cost of products sold | |||||
| Depreciation and amortization | |||||
| Total operating costs | |||||
| Earnings from operations | |||||
| Interest expense | |||||
| Loss on sale of subsidiary and subsidiaries held for sale | |||||
| Total income before income taxes | |||||
| Provision for income taxes | |||||
| Net earnings | |||||
| Earnings attributable to noncontrolling interests | |||||
| Net earnings attributable to UnitedHealth Group common shareholders | |||||
| Earnings per share attributable to UnitedHealth Group common shareholders: | |||||
| Basic | |||||
| Diluted | |||||
| Basic weighted-average number of common shares outstanding | |||||
| Dilutive effect of common share equivalents | |||||
| Diluted weighted-average number of common shares outstanding | |||||
| Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |
Loading...
